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ABSTRACT 
We evaluated the contribution of patient specific clinical and genetic factors to statin-
related muscle toxicity (SRM) without significant creatine kinase elevation (125 cases related 
to simvastatin or atorvastatin and 481 controls). The association between 12 SNPs in nine 
candidate genes and clinical factors with SRM was evaluated. Of the 12 SNPs genotyped, 
only rs4149056 in SLCO1B1 was associated with SRM in univariate analysis (with any statin, 
OR=1.73, 95 % CI= 1.14-2.62, P = 0.010) and this association was influenced by sex (P= 0.006) 
and BMI (P=0.02). In multivariate and binary logistic regression analyses, SLCO1B1 
rs4149056 genotype (OR=1.66, 95% CI: 1.08-2.54, P=0.014) and sex (OR=1.72, 95% CI =1.15 - 
2.59, P=0.006) were independently associated with muscle toxicity related to statin 
treatment. Patient-specific genetic and clinical factors associated with increased systemic 
exposure to statins are implicated in the full spectrum of SRM, including myalgia in addition 
to severe myopathy.  
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INTRODUCTION 
 
Although statins are generally well tolerated, statin-associated side-effects are a common 
problem in routine clinical practice, leading to dose reduction, non-adherence or 
discontinuation of therapy, with consequent poor control of LDL-cholesterol and increased 
risk of preventable cardiovascular morbidity and mortality (1). Statin-associated 
musculoskeletal symptoms (SAMS) without significant elevation of creatine kinase is the 
most common adverse event leading to discontinuation of therapy (2).  However, therapy 
can be restored in the majority of statin-intolerant patients when re-challenged (3). Indeed, 
in large clinical trials, minor muscle symptoms occur at similar frequency, regardless of 
allocation to statin or placebo suggesting that in most patients, SAMS are not of 
pharmacological origin (4, 5). Conversely, true statin-related muscle toxicity (SRM), with 
characteristic symptoms which resolve quickly on discontinuation of therapy and recur with 
re-challenge, is demonstrated in only a minority of SAMS cases under double-blind 
conditions (6, 7). The phenotype of SRM ranges from tolerable myalgia to intolerable muscle 
pain and weakness with elevation of creatine kinase (CK) due to breakdown of muscle tissue 
mandating immediate withdrawal of statin therapy (8). The graded classification proposed 
by Alfirevic et. al. (8) defines this spectrum on a scale of 0-6 according to the severity of 
symptoms, CK elevation and end organ damage. Although more severe forms of muscle 
toxicity, such as myopathy and rhabdomyolysis (SRM4-5), are infrequent even at higher 
statin doses (8, 9) , clinicians considering re-challenge in patients intolerant of the high 
intensity statin regimes recommended for effective cardiovascular prevention face a difficult  
decision - how to distinguish patients with minor muscle symptoms of non-pharmacological 
origin from those with “true SRM” of moderate severity (SRM 2-3) who are at risk of 
progression to more severe myopathy, and in whom the high cost, non-statin alternative 
therapies such as PSCK9 inhibitors may be justified.   
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There is consistent evidence that patient-specific clinical factors, such as advanced age (10), 
female sex (11, 12), low body mass (13), hepatic and renal dysfunction (14) and drug- drug 
interactions (15), contribute to SRM (16). There is also compelling evidence that genetic 
factors, including those that influence statin disposition and localization in skeletal muscle 
increase the risk of SRM in susceptible individuals (16). The best genetic predictor for severe 
forms of statin-related myopathy is the rs4149056 polymorphism in the SLCO1B1 gene, 
which codes for the organic anion-transporting polypeptide OATP1B1 (9).  The existence of 
an association between SLCO1B1 rs4149056 and simvastatin-induced myopathy has a well-
established pharmacokinetic basis (17) and has been confirmed in clinical studies by several 
investigators (18-21) but is clearly demonstrated only at higher doses and when CK elevation 
is included in the definition of SRM(18, 22) but not at lower doses of statins or milder 
SRM(23). It is less clear whether this genetic variant is a useful predictor of SRM with 
atorvastatin, the most widely prescribed high potency statin (24). However, the association 
between statin use and myopathy is a class effect and if less severe SRM is pharmacological 
in origin, an association might be expected with common variants in SLCO1B1 or other genes 
related to statin disposition and muscle exposure, including those involved in drug 
metabolism and muscle membrane transport (25, 26). Thus, the possible contributions of 
common SNPs in a selection of these genes, together with patient specific clinical factors, 
were evaluated in patients treated with the highest recommended doses of simvastatin and 
atorvastatin in a lipid clinic based case-control study, designed to include the less severe end 
of the SRM spectrum (SRM2) which most commonly accounts for discontinuation of therapy 
in routine practice (8). 
 
 
RESULTS 
Characteristics of study subjects 
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A total of 606 patients [125 cases and 481 controls], all of whom were of self-reported 
European ancestry were recruited into the study. The demographic and clinical 
characteristics of the study cohorts are summarized in Table 1. All cases reported myalgia 
without significant CK elevation (>4 times ULN) and were classified as SRM2. One case 
deteriorated to SRM4 (severe myopathy) but was later diagnosed as polymyositis, not statin-
related and was therefore excluded from the data analysis. In the case group there was a 
significantly greater proportion of females than the control group (58.4% vs 44.1 %; 
P=0.004). A greater proportion of patients in both the case and the control groups were 
treated with simvastatin than atorvastatin (107 of 125, 85.6 % and 297 of 481, 61.7 % 
respectively; P < 0.001). In both groups, simvastatin 40 mg/day was the most frequently 
prescribed while the most common dosage regimen for atorvastatin was 80 mg/day (Table 
1). The mean age of the controls (60.93 years; 95 % CI: 59.82 –62.05) and the cases (60.29 
years; 95 % CI: 58.10 -62.48) were similar.  There was no significant difference in BMI 
between the cases (median 28.5 kg/m2, interquartile range 26.4 - 31.7) and the controls 
group (median 28.5 kg/m2, interquartile range 25.8 -32.0). There was a marked difference 
(P<0.001) in total duration of statin treatment between the cases (median 8 months, 
interquartile range 3 -18) and the controls (median 24 months, interquartile range 12 - 65). 
There was no significant association between SRM and the presence of comorbidities 
reported to enhance the risk of SRM, such as type 2 diabetes, impaired renal function, 
hypothyroidism and hypertension.  Approximately 17-30 % of the cases and of controls 
reported concurrent exposure to drugs which have the potential to interact with the 
pharmacokinetics of statins, including fibrates, calcium antagonists and CYP3A4 inhibitors. 
However with the exception of warfarin (fewer patients in the case group; p =0.008) and 
dihydropyridine calcium antagonists (fewer patients in the control group; p= 0.031) the 
patient-reported use of such agents was similar in cases compared to the controls.  A list of 
all concomitant medications deemed to interact with statins which were taken by the study 
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patients is provided in the supplementary Table S1. Compared to the control subjects, cases 
had higher concentrations of serum lipids at the time of recruitment, on maximum tolerated 
lipid lowering therapy, which were well above recommended treatment goals for high risk 
primary and secondary prevention (Table 1). 
Environment-gene association with SRM 
The genotype frequencies of all tested SNPs were checked for their consistency with Hardy-
Weinberg Equilibrium (HWE) (Table 2). Frequencies for one SNP, rs1050450 in GPX1 were not 
in Hardy-Weinberg equilibrium and this SNP was not studied further. Of the remaining 12 
SNPs studied, none were significantly different to the frequencies reported in the GBR 
(British in England and Scotland) derived from 1000 genomes browser 
(http://browser.1000genomes.org/index.html) and met the analysis criteria of having a 
minor allele frequency >0.01. Subsequently these 12 SNPs were included in further analyses. 
All SNPs were successfully genotyped in 99.2 % of the patients (blood samples were missing 
for 5 individuals belonging to the control group). When these 12 SNPs were tested in 
dominant models (Table 2) in a univariate analysis, only the SNP in SLCO1B1 [rs4149056, 
(c.521T>C; V174A)] was associated with SRM (P=0.010). There was a significantly higher 
proportion of carriers of the minor C allele (heterozygotes and homozygotes) in the case 
group, irrespective of the type of statin used, compared to the controls; 37.6 % vs 25.8 % 
(Figure 1-A) with odds ratio (OR) of 1.73 (95% CI: 1.14- 2.62). There was no significant 
difference in the frequency of C allele carriers between the simvastatin and atorvastatin 
intolerant cases (Figure 1-B). Polymorphisms in other genes, including SNPs in previously 
proposed gene candidates for SRM i.e. GATM (rs9806699) and COQ2 (rs4693075), showed 
no significant difference between cases and controls. 
In multivariate logistic regression analyses adjusted for patient age, sex, BMI and the 11 
remaining genotypes, SLCO1B1 rs4149056 (OR=1.72, 95% CI: 1.15- 2.59; P=0.014) and 
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female sex [OR=1.72 (95% CI =1.15 - 2.59; P=0.006)] were the only variables which were 
independently associated with SRM (Table 3). In the statin-intolerant group the relative risk 
of SRM was higher in females and it increased further in patients with C variant allele 
irrespective of sex (Table 4). In the C allele carriers, the BMI was significantly lower in the 
cases (N=47, Mean BMI 27.9 kg/m2) than the controls (N=123, Mean BMI 29.8 kg/m2) a 
mean difference in BMI of 1.9 kg/m2 (P=0.02).  
According to binary logistic regression analysis only sex (P=0.004), SLCO1B1 genotype (P= 
0.011) and logged BMI in C allele carriers (P=0.014,) were found to be significantly 
associated with SRM.  
 
DISCUSSION 
A modern dilemma faced by clinicians who prescribe statins is how to decide which, if any, 
patients with muscle symptoms in the absence of significant CK elevation have “true” statin-
related muscle toxicity (SRM), related to the pharmacology of statins, and which have non-
specific musculoskeletal symptoms reflecting a high background prevalence in patients 
eligible for statin treatment.   In order to determine whether pharmacological factors 
contribute to less severe statin-related muscle toxicity in patients referred to a specialist 
lipid clinic, we examined the association between SRM2-3 defined by de-challenge and re-
challenge, and polymorphisms in candidate genes implicated in statin disposition and safety 
alongside patient demographics and clinical features.  Our findings of a clear association 
between SRM2 and both the SLCO1B1 rs4149056 polymorphism and sex is consistent with 
findings reported previously in both moderate and severe cases (9, 15, 18) which provides 
further evidence indicating that SRM of moderate severity is, at least in part, of 
pharmacological origin and appears related to altered systemic and muscular drug exposure.  
Therefore, the symptoms reported by patients with moderate SRM, as defined in our cohort, 
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cannot be attributed solely to a “nocebo effect” or misattribution of symptoms, and imply 
that tailored strategies for lipid lowering therapy may reduce the risk of SRM. 
Our findings of the association between female sex and SRM is in concordance with previous 
findings from clinical trials (9, 18) and epidemiological studies reporting that, female sex 
(linked to small body frame), along with patient age and frailty, increase susceptibility to 
SRM(27). In the entire study cohort, we found no association between patient age and BMI 
and SRM; however, the SLCO1B1 C allele carriers in the case group, irrespective of age, had a 
significantly lower BMI. Our data supports the view that low BMI is an endogenous risk 
factor for SRM (2, 28), perhaps because low BMI, which is linked to smaller vascular volumes 
and reduced muscle mass, could lead to greater statin systemic exposure, thus exacerbating 
the risk of SRM, particularly in the C allele carriers. 
Systemic exposure to statins appears to be attributable, to an extent, to the SLCO1B1 
rs41490565 polymorphism resulting in altered hepatic drug uptake. It has been 
demonstrated that, relative to the wild-type TT genotype, homozygosity for the C allele 
increases the area under the plasma concentration versus time (AUC) by 221% for active 
simvastatin acid (29), significantly more than for other statins, including pitavastatin (162%-
191%), atorvastatin (144%), pravastatin (57 %-130%), rosuvastatin (62%-117%) and least for 
fluvastatin (19%) (15). Although previous studies have shown conflicting results on the 
susceptibility to SRM with other statins (11, 18, 20, 21, 30), there may be an increased risk 
for SRM among SLCO1B1 rs4149056 carriers using atorvastatin, as suggested by Pasanen and 
colleagues (31). Whether SLCO1B1 rs4149056 truly confers susceptibility among 
atorvastatin-intolerant cases remains inconclusive but the effects of the variant on the 
pharmacokinetics of atorvastatin (31) are certainly smaller than seen with simvastatin (32). 
It is also known that hepatic uptake of atorvastatin is mediated not only by OATP1B1 but 
also by OATP1B3 (33) and atorvastatin and its lactone appear to have lesser inhibitory effect 
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on mitochondrial complex III activity (34).  In the present study, we found no evidence of 
contributions from any of the newly proposed candidate genes toward SRM. Surprisingly, we 
found no association between CYP3A4*22 and SRM, even though the SNP rs35599367 has 
been associated with reduced CYP3A4 activity, which is involved in the metabolism of both 
simvastatin and atorvastatin and has been previously demonstrated to contribute to 
variability in simvastatin efficacy in the Dutch population (35).  
In our study, patients were identified as SRM cases on the basis of having received either 
simvastatin or atorvastatin and discontinued treatment because of intolerable muscle 
symptoms which later resolved on drug withdrawal and recurred on re-challenge, without 
significant increase in CK.  As the statin rechallenge was unblinded and often undertaken 
prior to referral we expect that a proportion of cases who failed rechallenge without CK 
elevation did not have true SRM as has been demonstrated by double-blind rechallenge with 
statins(7).  While measurement of CK is recommended as a biomarker of muscle damage in 
symptomatic patients (9, 14, 36) and is important for classifying SRM according to severity, it 
is non-specific and cannot be used alone for establishing SRM.  Since CK levels during initial 
exposure were frequently unavailable (at the time of recruitment the majority of cases had 
already stopped statin therapy), we cannot exclude the possibility that the severity grading 
in some of our patients may have been underestimated, potentially misclassifying SRM3 or 
even SRM4 cases as SRM2.  However, this is also likely to reflect the situation in clinic 
practice and although challenging, prompt measurement of CK in symptomatic patients 
remains of central importance for the clinical assessment of SRM.   
Our study suggests that, among people of European ancestry, SLCO1B1 rs4149056 is a 
predisposing factor for SRM across the full spectrum of severity (SRM2 or greater) with 
simvastatin and atorvastatin at the highest recommended dose (40 mg and 80 mg 
respectively).  It has been proposed that the SLCO1B1 rs4149056 polymorphism may help 
identify patients at risk of progression to more severe statin-related myopathy.  For 
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simvastatin users, possession of the C allele had a diagnostic sensitivity and specificity of 
70.4% and 73.7%, respectively, giving positive and negative likelihood ratios of 2.7 and 0.4 
for the prediction of definite or incipient myopathy during 5 years of 80 mg/day simvastatin 
use (37).  However, in view of the low positive predictive value for progression to severe 
myopathy and high frequency of the C allele in statin tolerant patients, in our opinion the 
possession of the C allele is not a clinically useful diagnostic test to identify patients at risk of 
SRM. 
In conclusion, our results demonstrate that symptoms reported by patients with SRM of 
moderate severity are at least in part, of pharmacological origin and cannot be attributed 
solely to a “nocebo effect”.  SLCO1B1 rs4149056 genotype is an important susceptibility 
factor which together with female gender, is associated with the full spectrum of SRM seen 
in patients treated with high doses of simvastatin and atorvastatin. However, we found no 
association between SRM and polymorphisms in any of the newly proposed gene candidates 
studied, and an accurate, predictive diagnostic test for susceptibility to SRM remains elusive. 
In view of their proven safety and low cost, statins will remain in clinical use for the 
foreseeable future. Therefore, in order to improve the already overwhelmingly positive 
benefit-risk ratio of statins clinicians must adopt a pragmatic approach to reduce the risk of 
SRM when prescribing statins, where possible avoiding the use of simvastatin which has the 
greatest potential for toxicity, by choosing lower initiation doses in women and other 
patients with lower body mass index and by avoiding co-administration of potentially 
interacting drugs.   
 
METHODS 
 
Patient recruitment, blood collection and case definitions 
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Ethical approval for the study was provided by NRES Committee North East - County Durham 
& Tees Valley. Patients requiring statin therapy for primary or secondary prevention of 
cardiovascular disease were recruited between May 2011 and October 2014 from 
outpatients attending the Lipid and Cardiology Clinics at the Royal Victoria Infirmary, 
Newcastle upon Tyne.  Patients who had received a daily dose of simvastatin 40 mg or 
atorvastatin 80 mg (the two most commonly prescribed statins in our locality) for at least 6 
months without new onset of muscle symptoms were defined as the statin tolerant control 
group. Patients who had previously received either simvastatin 40 mg or atorvastatin 80 mg 
but had discontinued the drug because of new muscle symptoms (intolerable muscle pain or 
weakness, with or without elevation of creatine kinase, onset within 6 months of starting 
therapy) which resolved on withdrawal and recurred with re-challenge at the same or a 
reduced dose were considered to have SRM and to be eligible for recruitment as cases.  In 
each case the severity of muscle toxicity was graded according to the classification system 
based on the severity of muscle related symptoms (tolerable or intolerable) and the CK 
elevation (less than 4 times the upper normal limit in SRM2) proposed by Alfirevic and co-
workers (8).   The local laboratory reference ranges for creatine kinase were as follows: Male 
10-190 U/L; Female 10-160 U/L.  
 
After obtaining informed written consent, the medical records of those previously intolerant 
of simvastatin and/or atorvastatin were reviewed and a structured face-to-face interview 
was conducted by a trained research nurse. Patient demographics (including age, sex, height 
and weight), co-morbidities and medications were recorded. The indication for statin 
therapy, the daily doses and type of statins used and the regional distribution and temporal 
pattern of symptoms of muscle pain or weakness were recorded.  In addition to routine 
serum biochemical measurements, each patient provided a venous blood sample (4 ml) 
which was transferred into EDTA tubes and stored at -80 °C for later genotyping.  
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Single nucleotide polymorphism (SNP) selection, DNA extraction and genotyping 
SNPs of known functional significance were selected based on previous findings(9, 11, 38-
42). Additionally, rs1050450 and rs713041 in glutathione peroxidases 1 and 4 (GPX1 and 
GPX4), respectively, were selected on the basis of decreased GPX activity associated with 
these SNPs reported by several previous studies (43-47) (Table 5). While there is evidence 
for the involvement of OATP2B1 and various multidrug resistance-associated proteins 
(MRPs) in transport of statins in striated muscle (48), there is no information available on 
the involvement of monocarboxylate transporters (MCTs), which are abundantly expressed 
in the skeletal muscle, and their polymorphisms in relation to SRM.  We hypothesized that 
SRM could be promoted by the increased uptake of statins and/or accumulation of 
endogenous monocarboxylate metabolites (e.g. lactate) in skeletal muscle which mainly 
involve MCTs, possibly MCT1 and MCT4 (25, 26). Since there was no prior information 
available on the influence of either MCT1 (SLC16A1) or MCT4 (SLC16A3) gene on statin-
related myopathy, tag-SNP selection was employed for these two genes (Table 6) with tag-
SNPs in both MCT1 and MCT4 selected from the HapMap website 
(http://www.hapmap.org). The data from tagging approach from the HapMap website 
captured 100 % of alleles with mean r2 0.994 and 1.0, for the SLC16A1 and SLC16A3 genes, 
respectively. 
DNA extraction and genotyping 
DNA extraction was carried out using perchloric acid-chloroform extraction method as 
described by Daly and co-workers (49). Most SNPs were genotyped by TaqMan assays 
designed and supplied by Applied Biosystems in a ABI StepOne Real Time PCR system 
(Paisley, UK) under the following thermocycling conditions: 10 min at 95 °C followed by 40 
cycles of denaturation at 95 °C for 15s and annealing/extension at 60 °C for 1 min. 
Genotypes for polymorphisms in ABCC2 (rs717620) and ABCG2 (rs2231142) together with 
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one SNP in SLC16A1 (rs1049434) were determined by PCR-RFLP (50) using the conditions 
summarized in Table 6.  
Sample size calculation 
Assuming a rs4149056 SLCO1B1 minor allele frequency of 0.14 in our statin-tolerant 
patients, we calculated that a sample size of 600 patients (500 controls and 100 cases) with 
85% power would detect an OR of 2 at a significance value of 0.05. We hypothesized that a 
multitude of other factors contribute to intolerance to simvastatin and atorvastatin, 
including clinical and environmental factors and common variants in the genes that mediate 
statin systemic exposure. However, as there is no priori information available on the 
variance in drug exposure (plasma simvastatin/atorvastatin concentration), and the 
quantitative effect of each genetic variant and other confounders including patient 
characteristics on the risk of statin muscle toxicity, we considered this sample size to be 
sufficient to detect any association of comparable magnitude. 
Statistical analysis 
Statistical analyses for all clinical parameters (expressed as mean, standard deviation, 95 % 
confidence interval, CI) were performed using Minitab statistical software (version 16, 
Coventry, UK). For univariate analysis, chi-square statistics were used for categorical 
variables and t-tests for continuous variables. Where necessary data were log transformed 
to achieve normality. For multivariate analysis, by taking a dichotomous variable (cases vs 
controls) as dependent variable, binary logistic regression was performed to assess 
independent patient, clinical and genetic risk factor/s associated with the cases. Comparison 
of genotype frequencies for one or two variant alleles between cases vs controls was made 
using binary logistic regression; Hosmer and Lemeshow goodness-of-fit test was used as an 
indicator of the validity at the last step of iterations. A dominant model for genotypes [i.e. 
wild-type vs (heterozygous + homozygous genotype)] was used for all SNPs studied due to 
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homozygous mutants being rare.  For all analyses, a p-value of <0.05 was taken as being 
statistically significant. 
STUDY HIGHLIGHTS 
 What is the current knowledge on the topic? 
The existence of an association between SLCO1B1 rs4149056 and simvastatin-induced 
myopathy has been demonstrated only at higher drug doses and when CK elevation is 
included in the definition of statin-associated musculoskeletal symptoms. 
 What question did this study address?  
Are statin-associated muscle symptoms without significantly raised CK levels caused by 
statins or are they a nocebo effect? 
 What this study adds to our knowledge?  
Patient-specific genetic and clinical factors associated with increased systemic exposure to 
statins are implicated in the full spectrum of SRM, from myalgia to severe myopathy. 
 How this might change clinical pharmacology or translational science? 
Pharmacological mechanisms contribute to the full spectrum of SRM including myalgia 
without CK elevation. A wider understanding of the predisposing factors to SRM will enable 
clinicians to optimize management while minimizing untoward effects in susceptible 
patients. 
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FIGURE LEGEND 
 
Figure 1: Distribution of SLCO1B1 rs4149056 genotype between cases and controls (A) and 
between simvastatin and atorvastatin users in the case group (B)  
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Table S1: Proportion of patients taking drugs known to interact with statins 
 
Drug Control; n (%) Cases; n (%) 
Amiodarone 1(0.2) 0 (0.0) 
Ciclosporin 0 (0.0) 0 (0.0) 
Colchicine 0 (0.0) 2 (1.6) 
Azithromycin 2 (0.4) 0 (0.0) 
Clarithromycin 0 (0.0) 0 (0.0) 
Erythromycin 1 (0.2) 0 (0.0) 
Digoxin 9 (1.9) 1 (0.8) 
Amlodipine 29 (6.0) 14 (11.2) 
Lercanidipine 4 (0.8) 1 (0.8) 
Diltiazem 4 (0.8) 2 (1.6) 
Nifedipine 3 (0.6) 2 (1.6) 
Verapamil 2 (0.4) 1 (0.8) 
Ezetimibe 29 (6.0) 8 (6.4) 
Bezafibrate 0 (0.0) 1 (0.8) 
Fenofibrate 23 (4.8) 2 (1.6) 
Itraoconazole 0 (0.0) 0 (0.0) 
Ketoconazole 0 (0.0) 0 (0.0) 
Terbinafine 0 (0.0) 0 (0.0) 
Sildenafil 1 (0.2) 1 (0.8) 
Warfarin 51 (10.6) 3 (2.4) 
PPI (-prazole) 138 (28.7) 19 (15.2) 
Total 159 (33.1) 37 (29.6) 
Table 1: Demographic and clinical characteristics of statin-tolerant (controls) and statin-intolerant 
(cases) subjects 
Variables Controls  
(n=481)  
Cases  
(n=125)  
P-value 
 Sex 
         Female, N (%)  
         Male, N (%) 
  
212 (44.1%)  
269 (55.9%) 
 
73 (58.4%) 
52 (41.6%) 
  0.004 
Age at enrolment (years), mean (95 % CI)  60.9 (59.8-62.1)  60.3 (58.1 -62.5)  0.610 
Body mass index (kg/m2), median (LQ, UQ) 28.5 (25.8,  
32.0)  
28.5 (26.4,  
31.7) 
  0.933 
Duration on statin (months), median (LQ, UQ) 24 (12, 65) 8 (3, 18) <0.001 
Statin, N (%) 
 
       Simvastatin,  
              10 mg/day 
              20 mg/day 
              40 mg/day 
              80 mg/day 
 
      Atorvastatin,  
              10 mg/day 
              20 mg/day 
              30 mg/day 
              40 mg/day 
              80 mg/day 
 
 
297 (61.9)  
- 
4 (1.3)  
286 (96.3)  
7 (2.4) 
 
183 (38.2)  
1 (0.5) 
2 (1.1)  
1 (0.5)  
12 (6.6)  
167 (91.3) 
 
 
107¥ (85.6) 
 8 (7.5)  
15 (14.0)  
78 (72.9)  
4 (3.7) 
 
18# (14.4)  
1(5.6) 
- 
- 
1 (5.6)  
15 (83.3)  
<0.001 
 
 
Plasma lipids, mean (± SD) 
      Cholesterol, mmol/L       
      Triglyceride, mmol/L 
      HDL-cholesterol, mmol/L 
 
 
4.62 (1.72) 
1.85 (1.46) 
1.45 (0.45) 
 
 
6.45 (1.71) 
2.28 (1.49) 
1.48 (0.44) 
 
 
<0.001 
<0.001 
0.852 
 
Other medical conditions, N (%) 
Type 2 Diabetes 
Hypertension 
Hypothyroidism 
Chronic Kidney Disease 3A 
Chronic Kidney Disease 3B-5 
None 
 
 
53 (11.0) 
123 (25.6) 
28 (5.8) 
35 (7.3) 
32 (6.7) 
70 (14.6) 
 
 
8 (6.4) 
35 (28.0) 
11 (8.8) 
5(4.0) 
3 (2.4)  
20 (16) 
 
 
0.196 
0.543 
0.216 
0.249 
0.097 
  0.617 
Statin interacting drugs, N (%) 
Digoxin 
Fibrates  
CYP3A4 inhibitor  
Calcium antagonist (dihydropyridine) 
Calcium antagonist (non-dihydropyridine) 
Aspirin 
Warfarin 
Ezetimibe 
Sildenafil 
 
9 (1.9) 
24 (5.0) 
3 (0.6) 
36 (7.4) 
6 (1.2) 
148 (30.7) 
51 (10.6) 
29 (6.0) 
1 (0.2) 
 
2 (1.6) 
4 (3.2) 
0 (0) 
17 (13.4) 
3 (2.4) 
27 (21.6) 
3 (2.4) 
8 (6.4) 
1 (0.8) 
 
0.839 
0.396 
- 
0.031 
0.342 
0.129 
0.008 
0.877 
0.303 
¥ Initiation dose could not be confirmed for two individuals 
#Initiation dose could not be confirmed for one individual 
Table 2: Association between individual SNPs and SRM by univariate analysis 
 
*The rs1050450 SNP was excluded from subsequent analyses.  
a P-value for HWE calculated in control group and compared with CEU population. 
b Genotype results for all the SNPs investigated were unavailable for 5 individuals from control group. 
WT; wild type, Het; Heterozygous genotype, Mut; Homogenous mutants, OR; Odds ratio, ND; not determined. 
 
Gene and SNP Geno-
type 
Frequency, n 
 
Controlsb               Cases 
P-valuea P-value  OR 95% CI for OR 
SLCO1B1  
rs4149056 
WT 
Het 
Mut 
353  
112  
11  
78  
45 
2  
0.547 0.010  1.73 1.14- 2.62  
ABCC2  
rs717620 
WT 
Het 
Mut 
300 
158  
18  
80  
40  
5 
0.626 0.917 0.96 0.64-1.44 
ABCG2 
 rs2231142  
WT 
Het 
Mut 
374 
94  
7  
104  
19  
2  
0.690 0.318 0.75 0.45 -1.26 
CYP3A4 
rs35599367 
(*22) 
WT 
Het 
Mut 
422  
51  
2  
111  
14  
0  
0. 
729 
1.000 1.00 0.54-1 .88  
COQ2 
 rs4693075 
WT 
Het 
Mut 
190  
219  
66  
51 
57  
17 
0.856 0.918 0.97 0.65- 1.44 
GATM  
rs9806699 
WT 
Het 
Mut 
252  
175 
47  
64 
48  
13 
0.052 0.763 1.08 0.73-1.61  
*GPX1 
rs1050450 
WT 
Het 
Mut 
245 
160 
54 
63 
52 
10 
<0.001 ND ND ND 
GPX4 
rs713041 
 
 
SLC16A1 
rs1049434  
 
 
rs3849174 
 
 
 
rs4301628 
 
 
SLC16A3 
rs7503429 
 
 
 
rs12453290 
WT 
Het 
Mut 
 
WT 
Het 
Mut 
 
WT 
Het 
Mut 
 
WT 
Het 
Mut 
 
WT 
Het 
Mut 
 
WT 
Het 
Mut 
137 
251  
84  
 
130  
254  
88 
 
308  
151  
16  
 
206  
219  
50 
 
130  
236 
103  
 
217  
219 
40 
34  
68 
23 
 
39 
59 
27 
 
70  
51 
4 
 
63  
52 
10 
 
36  
82  
7 
 
64 
47 
14  
0.106 
 
 
 
0.059 
 
 
 
0.639 
 
 
 
0.437 
 
 
 
0.797 
 
 
 
0.128 
0.739 
 
 
 
0.435 
 
 
 
0.077 
 
 
 
0.189 
 
 
 
0.823 
 
 
 
0.270 
1.09 
 
 
 
0.84 
 
 
 
1.45 
 
 
 
0.75 
 
 
 
0.95 
 
 
 
0.80 
0.70-1.70 
 
 
 
0.55-1.29 
 
 
 
0.97-2.16 
 
 
 
0.51-1.12 
 
 
 
0.61-1.47 
 
 
 
0.54-1.18 
Table 3: Association between patient sex, rs4149056 SNP and SRM (adjusted for patient age, sex, 
BMI and other 11 genotypes) according to binary logistic regression analysis 
 
Dependent 
Variables 
Controls Cases  Explanatory variables P-value#  OR 95% CI for 
OR¶  
Statin-related  
muscle 
toxicity 
481*  125* Patient sex 
SLCO1B1 (rs4149056) 
ABCC2 (rs717620)  
ABCG2 (rs2231142)  
CYP3A4*22 (rs35599367) 
COQ2 (rs4693075) 
GATM (rs9806699) 
GPX4 (rs703041) 
SLC16A1(rs1049434) 
SLC16A1(rs3849174) 
SLC16A1 (rs4301628) 
SLC16A4 (rs7503429) 
SLC16A4 (rs12453290) 
0.006  
0.014 
0.800 
0.228 
0.884 
0.837  
0.747  
0.733 
0.456 
0.121 
0.406 
0.990 
0.310  
1.72  
1.66 
0.96  
0.74  
0.98  
0.98  
1.03  
1.09  
0.83  
1.29  
0.80 
 0.95  
0.81  
1.15-2.59 
 1.08-2.54  
0.64-1.49 
0.44-1.25 
0.52-1.86 
0.65-1.48  
0.68-1.54  
0.69-1.70 
0.49-1.44 
0.78-2.04 
0.49-1.33 
0.61-1.51 
0.54-1.22  
 
* Genotypes from 6 individuals (5 in controls and 1 case) were not included in the analysis. 
# P-value for comparison of genotypes frequencies possession of one or two variant alleles between 
cases vs controls  
¶ Odds ratio describes the odds to be a case relative to a control when having at least one variant 
allele (or being female). 
 
Table 4: The relative risk of SRM in male and female SLCO1B1 rs4149056 carriers (TC+CC genotypes) 
compared to wild-type (TT genotype) and wild-type female compared to male (TT genotype)  
 
Category OR  95 % CI P-value 
Male (TC +CC) vs male TT genotypes 
Female (TC +CC) vs female TT genotypes   
Female TT vs Male TT genotype 
2.43 
2.93 
2.25 
1.3140, 4.4843 
1.5847, 5.4279 
1.3550, 3.7212 
0.0046 
0.0006 
0.0017 
 
Table 5: SNPs selected for genotyping on the basis of previous genotyping studies on SRM  
 
Gene  
 
SNP  
 
Evidence of the association with SRM/ 
reason for the selection  
 
Reference(s)  
 
SLCO1B1  
 
 
 
rs4149056  
 
Encodes a liver-specific member of the 
organic anion transporter family. The protein 
is involved in the removal of drug 
compounds such as statins. OR for SRM = 
4.5.   
 
(9, 18) 
ABCC2  
 
 
 
rs717620  
 
Protein encoded by this gene is included in 
the superfamily of ATP-binding cassette 
(ABC) transporters. ABC proteins transport 
various molecules across extra- and intra-
cellular membranes. Associated with 
switches to other cholesterol-lowering drugs 
during simvastatin therapy. 
 
 
 
(38) 
ABCG2  
 
 
 
rs2231142  
 
Protein encoded by this gene is included in 
the superfamily of ATP-binding cassette 
(ABC) transporters. ABC proteins transport 
various molecules across extra- and intra-
cellular membranes. Polymorphism markedly 
affects PKs of simvastatin acid.  
 
 
(40, 42) 
 
CYP3A4  
 
 
 
 
rs35599367  
(*22 allele)  
Encodes a member of the cytochrome P450 
superfamily of enzymes. The cytochrome 
P450 proteins are monooxygenases that 
catalyze many reactions involved in drug 
metabolism and synthesis of cholesterol, 
steroids and other lipids. Associated with 
statin metabolism and response.  
 
(35, 39, 42)  
 
COQ2  
 
 
 
 
rs4693075  
 
Encodes an enzyme that functions in the 
final steps in the biosynthesis of CoQ 
(ubiquinone), a redox carrier in the 
mitochondrial respiratory chain and a lipid-
soluble antioxidant. Polymorphism 
associated with statin intolerance and 
myopathy.  
 
(11)  
 
GATM  
 
 
 
 
  
rs9806699  
 
 
 
 
 
Gene encodes a mitochondrial enzyme that 
belongs to the amidinotransferase family. 
The enzyme is involved in creatine 
biosynthesis. Meta-analysis odds ratio for 
SRM for this polymorphism = 0.60  
 
 
(41)  
 
 
  SLC16A1   rs9429505 Encodes for the monocarboxylate 
transporter (MCT1) which is abundantly 
expressed in the membrane of striated 
muscle. 
 
 
(26) 
SLC16A3 rs7503429 Encodes for the monocarboxylate 
transporter (MCT4) which is abundantly 
expressed in the membrane of striated 
muscle. 
 
(26) 
 
 
Table 6 : Tag SNPs in SLC16A1 and SLC16A3 genes selected for genotyping and the primers, PCR conditions and restriction enzymes used for ABCC2 
(rs717620), ABCG2 (rs2231142) and SLC16A1 (rs1049434) genotyping by PCR-RFLP 
Gene Test 
 
Alleles 
captured 
Assay Primer set PCR conditions¶ PCR 
product 
(bp) 
Restriction enzyme 
(Recognition site) 
SLC16A1 
(MCT1)  
  rs9429505  rs7552903, 
rs4839272, 
rs2149036, 
rs4839270, 
rs3849174, 
rs7536532, 
rs9429505, 
rs7518984  
 
ABCC2 
rs717620 
 
Forward 
5’-TGTCCATCCACTGTTTCAATG - 3’ 
Reverse 
5’-CTGGACTGCGTCTGGATC- 3’ 
 
Annealing at 54°C for 1 min 
 
193 
 
TaqI (TCGA) 
rs7556664 rs3789592, 
rs7169, 
rs1049434, 
rs6537765, 
rs7556664  
rs12028967 rs4301628, 
rs12028967 
 
ABCG2  
rs2231142 
Forward 
5’- GTCTCATTAA AATGCTATTT - 3’ 
Reverse 
5’- CTCTTGAATG ACCCTGTTGA - 3’ 
 
Annealing at 50°C for 35 
sec 
 
151 
 
MseI (TTAA) 
SLC16A3 
(MCT4)  
rs7503429  
rs12453290   
rs7503429  
rs12453290  
 
SLC16A1 
rs1049434 
Forward 
 5’- TCAATGAACAACTGGTATGA- 3’ 
Reverse 
5’- ATGGAGACTACAAATACACA-3’ 
 
Annealing at 55°C for 1 min 
 
387 
 
BccI (CCATC) 
SNPs in bold text were chosen for genotyping based upon MAF >0.20 value obtained from 1958 British birth cohort website 
http://www.b58cgene.sgul.ac.uk/.  
 
¶Apart from the annealing temperatures described above, all PCR assays involved 35 cycles, with denaturation at  94°C for 1 min, extension at 72ºC for 1 
min and were held in the last cycle at 72ºC for 7 min to ensure elongation except for rs2231142. For rs2231142, the period for each step in each cycle was 
35 sec instead of 1 min. The ABCG2 and SLC16A1 assays were developed for this project. The ABCC2 assay was described previously (42).  
